Results 11 to 20 of about 3,056 (181)

In-vitro interaction studies between the amyloid PET tracer florbetaben and the amyloid-beta targeting antibodies lecanemab and donanemab on AD brain samples reveal no interferences [PDF]

Alzheimer’s Research & Therapy
Background Amyloid PET imaging enables the in vivo visualization and quantification of amyloid-beta deposits in the brain. In research and clinical settings, it is further used to monitor amyloid-beta burden as well as the biological response to disease ...
Andre Mueller, Aleksandar Jovalekic, Marianne Chapleau, Julius Seidel, Maria Ritter, Eva-Maria Bickel, Nadine Kiessling, Emer MacSweeney, Andrew W. Stephens, Norman Koglin   +9 more
doaj   +3 more sources

Unraveling Alzheimer’s: the promise of aducanumab, lecanemab, and donanemab

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
Alzheimer’s disease (AD) is a neurodegenerative condition that causes cognitive decline, memory loss, and reduced personal autonomy. The pathology of AD involves the aggregation of abnormal brain proteins, specifically beta-amyloid plaques and tau ...
Taha Basit Ameen, Syeda Naveera Kashif, Syed Muhammad Iraj Abbas, Kulsoom Babar, Syed Muhammad Sinaan Ali, Abdul Raheem   +5 more
doaj   +3 more sources

Donanemab in early symptomatic Alzheimer’s disease: results from the TRAILBLAZER-ALZ 2 long-term extension

The Journal of Prevention of Alzheimer's Disease
Background: Donanemab significantly slowed clinical progression in participants with early symptomatic Alzheimer’s disease (AD) during the 76-week placebo-controlled period of TRAILBLAZER-ALZ 2.
Jennifer A. Zimmer, John R. Sims, Cynthia D. Evans, Emel Serap Monkul Nery, Hong Wang, Alette M. Wessels, Giulia Tronchin, Shoichiro Sato, Lars Lau Raket, Scott W. Andersen, Christophe Sapin, Marie-Ange Paget, Ivelina Gueorguieva, Paul Ardayfio, Rashna Khanna, Dawn A. Brooks, Brandy R. Matthews, Mark A. Mintun   +17 more
doaj   +2 more sources

Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical Trials

Healthcare, 2022
Amyloid-β (Aβ) plaques and aggregated tau are two core mechanisms that contribute to the clinical deterioration of Alzheimer’s disease (AD). Recently, targeted-Aβ plaque reduction immunotherapies have been explored for their efficacy and safety as AD treatment.
Areeba Rashad, Atta Rasool, Muhammad Shaheryar, Azza Sarfraz, Zouina Sarfraz, Karla Robles-Velasco, Ivan Cherrez-Ojeda   +6 more
openaire   +3 more sources

Infusion‐related reactions in donanemab‐treated participants with early symptomatic Alzheimer's disease

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION Infusion‐related reactions (IRRs) and hypersensitivity are adverse events associated with therapeutic antibodies. Characterization of IRRs can lead to improved risk anticipation and management of this event.
Paul Ardayfio, Garrett R. Mullins, Rashna Khanna, Jennifer A. Zimmer, Hong Wang, Emel Serap Monkul Nery, Cynthia D. Evans, Pawel Piela, Chakib Battioui, Steve Lauzon, Greg Anglin, Hui Wen Ng, Anu Rita Jayaraman, Noah Agada, Chitra R. Natalie, Dawn A. Brooks, John R. Sims   +16 more
doaj   +2 more sources

FDA Approval of Donanemab‐azbt: A New Dawn in Alzheimer's Disease Treatment [PDF]

Health Science Reports
Background Alzheimer's disease (AD) is a neurodegenerative condition marked by the accumulation of beta‐amyloid plaques and neurofibrillary tangles, leading to neuronal death and cognitive decline.
Rumaisa Riaz, Marrium Fatima, Sadia Ramzan, Diya Rathi, Filzah Fatima, Maha Farooq, Ayesha Shaukat, Nawal Khaliq, Aymar Akilimali   +8 more
doaj   +2 more sources

Donanemab immunogenicity in participants with early symptomatic Alzheimer's disease

Alzheimer's and Dementia: Translational Research and Clinical Interventions
INTRODUCTION Donanemab is an immunoglobulin G1 antibody that targets an N‐terminal truncated form of amyloid beta present in mature plaques. Treatment‐emergent (TE) anti‐drug antibodies (ADAs) were quantified in donanemab‐treated participants from two ...
Rashna Khanna, Dawn A Brooks, John R Sims   +2 more
exaly   +2 more sources

Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer’s Disease in the United States

Neurology and Therapy
Introduction The goal of this economic model is to estimate an economically justifiable price (EJP) for using donanemab for the treatment of early symptomatic Alzheimer’s disease (AD) in the United States based on clinical data from the phase 3 ...
Malaz Boustani, Erin G. Doty, Louis P. Garrison Jr, Lee J. Smolen, Timothy M. Klein, Daniel R. Murphy, Andrew W. Spargo, Mark Belger, Joseph A. Johnston   +8 more
doaj   +2 more sources

Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application

Chronic Diseases and Translational Medicine
Substantial research has been conducted to identify an efficient treatment for Alzheimer's disease (AD). Existing treatments, including cholinesterase inhibitors and N‐methyl D‐aspartate (NMDA) receptor antagonists, do not reverse or slow the disease ...
Nandhini Jayaprakash, Karthikeyan Elumalai   +1 more
doaj   +2 more sources

Re-evaluation of the efficacy and safety of anti-Aβ monoclonal antibodies (lecanemab/donanemab) in the treatment of early Alzheimer’s disease

Frontiers in Pharmacology
ObjectiveTo systematically evaluate the efficacy and safety of anti-Aβ monoclonal antibodies (Lecanemab/Donanemab) in the treatment of early Alzheimer’s disease (AD) and to provide evidence for rational clinical use.MethodsWe searched databases including
Haoyang Wang, Junying Pan, Mingming Zhang, Zengde Tan   +3 more
exaly   +3 more sources